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Research
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OBJECTIVES: Since the beginning of the coronavirus disease 2019 pandemic, hundreds of thousands of patients have been treated in ICUs across
the globe. The severe acute respiratory syndrome–associated coronavirus
2 virus enters cells via the angiotensin-converting enzyme 2 receptor and
activates several distinct inflammatory pathways, resulting in hematologic
abnormalities and dysfunction in respiratory, cardiac, gastrointestinal renal,
endocrine, dermatologic, and neurologic systems. This review summarizes
the current state of research in coronavirus disease 2019 pathophysiology within the context of potential organ-based disease mechanisms and
opportunities for translational research.
DATA SOURCES: Investigators from the Research Section of the Society
of Critical Care Medicine were selected based on expertise in specific
organ systems and research focus. Data were obtained from searches
conducted in Medline via the PubMed portal, Directory of Open Access
Journals, Excerpta Medica database, Latin American and Caribbean
Health Sciences Literature, and Web of Science from an initial search from
December 2019 to October 15, 2020, with a revised search to February 3,
2021. The medRxiv, Research Square, and clinical trial registries preprint
servers also were searched to limit publication bias.
STUDY SELECTION: Content experts selected studies that included
mechanism-based relevance to the severe acute respiratory syndrome–
associated coronavirus 2 virus or coronavirus disease 2019 disease.
DATA EXTRACTION: Not applicable.
DATA SYNTHESIS: Not applicable.
CONCLUSIONS: Efforts to improve the care of critically ill coronavirus
disease 2019 patients should be centered on understanding how severe
acute respiratory syndrome–associated coronavirus 2 infection affects
organ function. This review articulates specific targets for further research.
KEY WORDS: angiotensin-converting enzyme 2 receptor; coronavirus
disease 2019; critical illness; pandemic; severe acute respiratory
syndrome–associated coronavirus 2

T

he coronavirus disease 2019 (COVID-19) pandemic caused by the
beta-coronavirus severe acute respiratory syndrome–associated coronavirus (SARS-CoV) 2 virus has resulted in more than 106 million cases and more than 2.32 million deaths (as of February 7, 2021) since
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emerging in December 2019 (1–3). Approximately,
20% of patients require hospitalization, and 25% of
those require ICU admission due to refractory hypoxemia, shock, or multiple organ failure (MOF)
(4–7). Numerous descriptive studies of COVID-19
pathophysiology, mechanism, signaling, and potential immunologic consequences have been published, but many reports lack integration and context.
COVID-19 victims do not succumb from the SARSCoV-2 infection per se; rather, mortality occurs due
to pneumonia, renal failure, thrombosis, and MOF
that reflect the innate immune signaling response
to the infection. The international community has
been much less focused on the ramifications of innate
immune signaling activation in COVID-19 (8).
In addition, analysis of COVID-19 outcomes further
exposes existing health disparities: Black and Hispanic
Americans are disproportionately impacted in terms
of morbidity and mortality. Additionally, males have
demonstrated lower survival rates (9–13). Although
these differences clearly indicate the need for evaluation of social determinants of health in COVID-19,
they may also reveal previously unrecognized mechanistic and signaling pathways that could be targeted
for potential therapeutics. This review summarizes the
current mechanisms and reported pathophysiology
of COVID-19 disease to characterize and understand
the illness and treatment. Since many patients present
with single organ disruption and/or current level of
evidence has been explored in specific organs, we present the known data in this fashion. We also explore
why organ disruption in the setting of COVID-19
(e.g., pneumonia, acute respiratory distress syndrome
[ARDS], renal failure) and the response to COVID-19
therapy appear to frequently differ from classical forms
of these pathologies.

OVERVIEW OF DISEASE
TRANSMISSION AND CLINICAL
FEATURES
SARS-CoV-2 is predominantly transmitted via respiratory droplets released by coughing or sneezing (14).
Similar to its predecessor SARS-CoV-1 (2003 SARS
outbreak), SARS-CoV-2 binds to the angiotensin-converting enzyme (ACE) 2 receptor via the virus Spike
protein (15). Host organs expressing the ACE2 receptor that are targets for the virus Spike protein are
presented in Figure 1. After binding, the furin domain
2     www.ccejournal.org

of the Spike protein is cleaved by host proteases (e.g.,
serine protease transmembrane protease, serine
[TMPRSS]2), which enables viral and cellular membrane fusion and subsequent internalization and release of the viral RNA (15). The ACE2 protein is widely
expressed on respiratory epithelium, which is the presumed entry point, although ACE2 protein expression
has been detected in many different organs (16).
Infected individuals may remain asymptomatic or
may develop a wide range of symptoms including fever,
malaise, anosmia, hypogeusia, sore throat, headache,
cough, shortness of breath, chest pain, nausea, abdominal pain, diarrhea, or cognitive changes. COVID-19
patients often present with lymphopenia, elevated
nonspecific inflammatory markers (C-reactive protein, lactic acid dehydrogenase [LDH], d-dimer, ferritin, aspartate aminotransferase [AST]), and patchy/
bilateral infiltrates on chest radiography. Patients who
proceed to critical illness typically develop shortness of
breath and hypoxemia within 5–8 days after symptom
onset and are more likely to be older, blood type A,
and have multiple comorbidities (7, 17–19). Critically
ill COVID-19 patients often require prolonged respiratory support and have high risk for MOF, thrombotic
coagulopathies, acute kidney injury (AKI), sudden
myocardial dysfunction, and prolonged hospitalization (20, 21).

REPORTED HOST IMMUNE
RESPONSES IN COVID-19
There are likely several SARS-CoV-2–induced inflammatory responses depending on host-pathogen interaction and disease evolution (summarized in Fig. 2).
Similar to other viral infections, viral replication and
cellular damage directly activate the host immune response, which contribute to the initial inflammatory
response (22). Viral replication induces host cell death
and the release of multiple danger-associated molecular patterns (DAMPs), which increase localized and
systemic inflammation via proinflammatory cytokine
and chemokine secretion (23). SARS-CoV-1 causes
pyroptosis and activates the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin
domain containing-3 inflammasome, further activating a proinflammatory cytokine cascade (24). Thus,
inflammasome activation may be one mechanism by
which SARS-CoV-2 recruits host immune cells to the
infection site, causing capillary leak, inflammatory
March 2021 • Volume 3 • Number 3
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Figure 1. Tissues expressing angiotensin-2 receptor (angiotensin-converting enzyme [ACE] 2) and related COVID-19 symptoms.
ARDS = acute respiratory distress syndrome, GI = gastrointestinal.

infiltrates, and pulmonary edema. Recent studies also
implicated neutrophil extracellular traps (NETs) in disease progression, although their impact as a driver of
downstream inflammation remains unclear (25–27).
Consensus is lacking on how to characterize the severity and nature of the inflammatory response. Several
early case studies in COVID-19 reported markedly elevated levels of interleukin (IL)–1β, IL-6, IL-10, tumor
necrosis factor (TNF)–α, and other mediators, leading
many to characterize it as a “cytokine storm.” However,
not every perturbation in a disease setting is maladaptive, and response severity measured at indiscriminate
time points does not necessarily correlate with pathogenicity. Distinguishing between appropriate and
dysregulated inflammatory responses in critically ill
patients remains challenging. Most cytokines induce
pleiotropic downstream effects with interdependent
biological activities, and interactions among these
mediators are neither linear nor uniform. The term “cytokine storm” implies that the elevated cytokine levels
are necessarily injurious to host cells, and widespread
acceptance of this term fueled the repurposing of many
immunotherapy drugs to suppress various inflammatory pathways. One approach to understanding these
responses has been to use the first 72 hours of temperature data from hospitalized COVID-19 patients
as a surrogate for the inflammatory response, thereby
Critical Care Explorations

allowing subphenotyping of patients (28, 29). Perhaps
not surprisingly, a subset of COVID-19 patients
manifests a dysfunctional “hyperinflammatory” response with persistent fevers and elevated inflammatory markers, whereas a separate subset manifests a
dysfunctional “hypoinflammatory” response, with an
absence of fevers and worse MOF (29). Thus, any discussion of the immune response in COVID-19 must
consider that although some patients mount an appropriate response and resolve the infection, others develop variably different dysfunctional responses which
manifest as different COVID-19 subphenotypes.
Consistent with a hypoinflammatory subphenotype, a significant proportion of COVID-19 patients
manifest a disease similar to immunoparalysis in
sepsis, which involves decreased human leukocyte
antigen (HLA)-DR expression and profound, persistent lymphopenia, including reductions in both CD4
and CD8 T cells. In addition, the remaining immune
cells in many COVID-19 patients are functionally impaired: monocytes have been shown to release less
TNF-α, whereas T cells release less IFN-γ and demonstrate increased PD-1 expression, consistent with
an exhausted phenotype (30–33). The observed downregulation of IL-2 and IL-7 in COVID-19 patients
indicates an impairment in the development, differentiation, and homeostatic expansion of T cells (34).
www.ccejournal.org
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Figure 2. Proposed host immune responses secondary to severe acute respiratory syndrome–associated coronavirus 2 (SARS-CoV-2)
infection. Although several host immune responses are activated by SARS-CoV-2 infection, all mechanisms appear to activate janus
kinase/signal transducer and activator of transcription (JAK/STAT), p38 mitogen-activated protein kinase (MAPK), and/or nuclear
factor–κB (NF-κB) pathways. This leads to release of proinflammatory cytokines (tumor necrosis factor [TNF] α, interleukin [IL]–6,
IL-1β) and chemokines (C-X-C motif ligand [CXCL] 1, CXCL10), and immune cell recruitment. Current evidence implicates three
potential mechanisms. 1) Direct viral infection induces host cell death and the release of multiple damage/danger-associated molecular
patterns (DAMPs), which increase proinflammatory cytokine and chemokine secretion. 2) Activation of NLRP3 inflammasome and
pyroptosis triggers a cascade of proinflammatory cytokines such as IL-1β. 3) Viral infection dysregulates the renin-angiotensin system
(RAS) by down-regulating the ACE2 receptor, which leads to decreased angiotensin (Ang) 1–7, increased AngII, and subsequent
AngII-receptor type 1 (AT1R) activation. This ultimately activates JAK/STAT, p38 mitogen-activated protein kinase (MAPK), and
NF-κB pathways and induces a proinflammatory state. CRP = C-reactive protein, NK = natural killer, NLRP3 = nucleotide-binding
oligomerization domain, leucine rich repeat and pyrin domain containing-3.

Such patients may benefit from immune stimulation,
rather than immune suppression. Indeed, recent work
suggests that treatment with the inhaled antiviral cytokine interferon-α2b results in accelerated viral clearance and reduced lung injury (35).
In contrast, the hyperinflammatory response subphenotype involves elevated levels of IL-6, IL-10, IL-8,
and chemokines (e.g., C-X-C motif ligand [CXCL]–8,
CXCL1, CXCL10, and C-C motif chemokine ligand-5)
(21, 34, 36–40). CXCL10 reflects recent IFN-γ activity
within 14 days, suggesting that the elevated CXCL10 levels at the time of ICU admission might be indicative of
increased T helper 1, natural killer (NK), or natural killer
T cell activity early in the illness, even though IFN-γ
4     www.ccejournal.org

levels were not elevated among these patients (34). TNFα levels range from low to normal or increased, indicating that the hyperinflammatory immune response is
distinct from the classical cytokine storm associated with
diseases like macrophage-activation syndrome in which
TNF-α is both a lead cytokine and a therapeutic target
(34). IL-1β levels are variable, reported as increased or
decreased, and there are currently trials using anakinra,
which blocks IL-1β activity, for treatment of the hyperinflammatory phase of COVID-19 (34).
Despite these overall patterns, IL-6 levels are orders of magnitude lower in patients with severe or
critical COVID-19 disease (median 26–210 pg/mL)
than in patients with non–COVID-19 ARDS (median
March 2021 • Volume 3 • Number 3
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578–1,618 pg/mL) (21, 36–43). Elevated IL-6 levels are
needed to activate and potentiate the adaptive immune
response and promote T cell regulation. By contrast, excessive IL-6 levels can block lymphopoiesis and induce
lymphocyte death (44). All distinct lymphocyte subsets
(NK cells, B cells, and T cells) may be affected by this
innate overactivation (34). The degree of IL-6 elevation
has been correlated with adverse outcomes in COVID19 patients and has led to trials of anti–IL-6 therapy for
COVID-19 patients, with variable success (45, 46).
Other contributors to the hyperinflammatory state
that are observed in many patients include dysregulation
of the renin-angiotensin system (RAS) and its interaction with the host immune response. ACE2 regulates
RAS homeostasis by cleaving angiotensin II (proinflammatory/profibrotic) into angiotensin 1–7, which leads to
an anti-inflammatory/antifibrotic/antioxidant response
(47–59). Angiotensin II is elevated in preclinical ARDS
models and elicits proinflammatory effects by activating
angiotensin II receptor type 1 (AT1R), nuclear factor–κB,
janus kinase/signal transducer and activator of transcription, and p38 mitogen-activated protein kinase pathways;
activation of these signaling pathways has stimulated interest in trials of kinase inhibitors for COVID-19. The
cleaved peptide (angiotensin 1–7) reduces inflammation by binding the Mas receptor to antagonize AT1R
(56). Previous studies report that SARS-CoV-1 infection
down-regulates ACE2 in mice, which correlated with severe acute lung pathologies mediated by increased angiotensin II and AT1R activation (57). Angiotensin II
was elevated in a small cohort of COVID-19 patients
and appeared to correlate with viral load and lung injury,
thus supporting the hypothesized role of RAS-immune
axis dysregulation (60).
The role of ACE2 in COVID-19 pathophysiology
led to hypotheses regarding the therapeutic use of ACE
inhibitors (ACEIs) and angiotensin receptor blockers
(ARBs) in patients with COVID-19. One hypothesis
suggests that ACEI-mediated ACE2 inhibition could
reduce morbidity and mortality by down-regulating
RAS (57). By contrast, ACEIs, and ARBs could hypothetically increase ACE2 expression, leading to
increased host susceptibility to viral invasion of target
cells (52). Several small observational studies investigated the clinical outcomes of these hypotheses in
patients with COVID-19, and current data suggest no
benefit or harm from ACEIs and ARBs on risk of developing COVID-19 or clinical outcomes (61, 62).
Critical Care Explorations

The primary site of SARS-CoV-2 infection in the
lungs is type 2 alveolar epithelial cells (AT2 cells).
Other cell types also express the ACE2 receptor and
may contribute to the multiple organ inflammatory
response observed in patients with COVID-19 disease. ACE2 expression is essentially ubiquitous and
has been detected in the brain, heart, oral and nasal
mucosa, nasopharynx, liver, kidney, lung, stomach,
small intestine, colon, skin, lymph nodes, thymus,
bone marrow, and spleen (16, 58). ACE2 expression
has been reported on lymphocytes, and SARS-CoV-2
viral particles can be detected in lymphocytes (63, 64).
Therefore, direct lymphocyte infection and cell death
may be responsible for lymphopenia in COVID-19
patients and explain the mechanism by which cytokine
release syndrome can develop in severe COVID-19
infections (65).
SARS-CoV-1 and SARS-CoV-2 have been isolated
from macrophages, and viral infection of these cells in
vitro appears to be associated with increased cytokine
release (66, 67). However, it remains difficult to distinguish these inflammatory mechanisms from direct
cellular infection effects due to ubiquitous ACE2 expression on immune cells (i.e., macrophages and dendritic cells) and in multiple organs. Alternatively, MOF
may be due to damage resulting from a combination
of the systemic inflammatory response or ongoing
immune suppression and persistent viral replication.
Finally, the emerging postinfectious inflammatory
syndrome in children (termed “multisystem inflammatory syndrome in children”) is likely mediated by
inflammatory cytokines, although this remains an area
of active exploration and will not be the subject of this
review (68).

METHODS
We performed a narrative review of the literature
retrieved from searches of Medline via the PubMed
portal, Directory of Open Access Journals, Excerpta
Medica database, Latin American and Caribbean
Health Sciences Literature, and Web of Science originally from December 2019 to October 15, 2020, and
revised twice to December 10, 2020, and February 3,
2021. We included data prior to December 2019 when
relevant for the reported or proposed mechanisms
in each organ system. Searches were not limited by
date, language, or publication status. Publication bias
www.ccejournal.org
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was limited by searching clinical trial registries including ClinicalTrials.gov, World Health Organization
International Clinical Trials Registry Platform, and
the Australian New Zealand Clinical Trials Registry.
We also searched the medRxiv and Research Square
preprint servers to limit publication bias. Grey literature was eligible for inclusion if the authors responded
affirmatively to correspondence with the requested
information.
We used the following National Library of Medicine
Mesh search terms: SARS-CoV-2 [Mesh], COVID-19
[Mesh], Middle East Respiratory Syndrome
Coronavirus [Mesh], SARS virus [Mesh]; Respiratory
Distress Syndrome [Mesh], and Pneumonia [Mesh].
Additional search terms included 2020 pandemic
and individual organ system terms. Articles were not
assessed using standardized and validated scales to
assess risk-of-bias or evidence quality. The data were
not pooled, so statistical analyses were not performed.

COVID-19 DISEASE MECHANISMS IN
ORGAN FAILURE
Respiratory Manifestations and Failure
SARS-CoV-2 was first identified via a bronchoalveolar lavage sample from a patient with severe ARDS in
Wuhan, China, indicating that the predominant location of viral replication and shedding is the respiratory tract (69). Patients with COVID-19 develop a wide
spectrum of pulmonary diseases with varying severities,
suggesting multiple mechanisms of disease propagation. Early evaluation of TMPRSS2 and ACE2 expression reported that both receptors were localized in nasal
epithelial cells and AT2 cells (16, 70). AT2 cells have a
critical role in normal pulmonary physiology because
they secrete surfactant and produce alveolar type 1 cells
during acute lung injury (ALI). Children have lower illness severity than their adult counterparts, which may
be partly explained by an age-dependent decrease in
ACE2 expression in nasal epithelium (71). The exact
mechanism of SARS-CoV-2 infection of AT2 cells is
under investigation, although it is clear that AT2 viral
infection leads to significant lung injury and may partly
explain pulmonary sequela observed in patients.
SARS-CoV-2 is a promiscuous virus with multiple
mammalian hosts and hijacks a variety of different
receptors and enzymes to invade cells. SARS-CoV-2
enters cells (by exploiting Spike protein sites) via ACE2,
6     www.ccejournal.org

dipeptidyl peptidase 4 (DPP4), CD147 (a highly glycosylated cell surface protein with wide tissue expression), or the cathepsin pathway to cleave and facilitate
viral entry (72–75). Blocking DPP4 attenuates ALI in
a murine model, and DPP4 has been studied in airway
remodeling and fibrosis, whereas CD147 has been
implicated in mucus hypersecretion (76–78). Thus,
identifying all receptors/proteases involved in SARSCoV-2 respiratory infection will enhance our mechanistic insight into disease pathogenesis.
Autopsy of COVID-19 patient lungs reveals several mechanistic clues for respiratory failure. First,
there is evidence of increased angiogenesis based
on imaging and gene expression data (79). Second,
COVID-19 patients with ARDS display significant
pulmonary fibrosis in the later disease stages, which
impairs oxygenation (80). Third, significant deposition of microthrombi is common and may partly explain the proposed “L” (low lung weight, low elastance,
and low inspiratory driving pressures) and “H” (high
lung weight, high elastance, and high inspiratory driving pressures) ARDS phenotypes (81), although some
experts have refuted the presence of the L phenotype. Fourth, COVID-19 patients are reported to have
increased susceptibility to ventilator-associated pneumonia, for as yet undefined reasons compared with
non–COVID-19 patients receiving invasive ventilation
(82). Respiratory effects also occur along with MOF,
profound alterations in coagulation, and hyperinflammatory cytokine profiles that are observed in other
critical illnesses. Inflammation and tissue injury do
not necessarily associate with the distribution of SARSCoV-2 RNA and protein in post mortem examinations
of lungs from COVID-19 patients, indicating that the
inflammatory response itself is responsible for much of
the respiratory failure (83).The extrapulmonary mechanisms by which SARS-CoV-2 infection triggers respiratory failure are discussed in subsequent sections.
Hematologic Dysfunction
COVID-19 disease significantly impacts the hematologic
system and hemostasis. Prothrombin time (PT) and activated partial thromboplastin time are prolonged and
d-dimer levels are elevated, suggesting the presence of a
consumptive coagulopathy such as disseminated intravascular coagulation. Diffuse alveolar hemorrhage has been
reported in COVID-19 patients, although a hypercoagulable phenotype with micro/macrothrombi formation
March 2021 • Volume 3 • Number 3
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in venous and arterial sites is more prevalent (12, 64,
65). Thrombi have been documented in the pulmonary,
renal, brain, hepatic, and cardiac vasculature. Marked
d-dimer elevation accompanied by normal or increased
platelet count and fibrinogen levels (84–86) is predictive
of severe disease in COVID-19 infection (62). This pattern, along with increased clot tensile strength without
increased fibrinolysis on thromboelastomeric assays in
COVID-19 patients (66), suggests that d-dimer elevation likely reflects the patient’s inflammatory response
rather than consumptive coagulopathy. This is supported
by differences in thrombi types between COVID-19
patients and other critically ill patients, and the reduced
effectiveness of anticoagulation therapy (either prophylactic or therapeutic) in COVID-19–related thrombosis
(87, 88).
It remains unclear why COVID-19–related coagulopathy generates a thrombotic phenotype rather than
a hemorrhagic phenotype. Recent data suggest that
the thrombotic phenotype likely results from specific
interactions between the host inflammatory response
(e.g., complement) and activation of coagulation,
platelets, and endothelial cells. SARS-CoV-2 infection promotes cytokine release through DAMPs, viral
nucleic acid recognition, and RAS axis disruption.
Reduced ACE2 levels may increase bradykinin levels (89), which may promote coagulopathy in at least
two distinct ways: 1) enhancing complement activation (27, 87) and 2) promoting neutrophil activation
and NET formation. Inflammation generally activates
the complement system, and subsequent depletion
of plasma complement is associated with increasing
disease severity and a prothrombotic state (Fig. 3)
(90–94). Separately, bradykinin-induced neutrophil
recruitment initiates a positive feedback pathway of
thrombin-mediated platelet activation promoting
NET formation, which further enhances inflammation
and platelet activation and leads to NET colocalization
with microthrombi (26, 95). Inhibition of NET formation reduces ARDS progression and thrombus formation in non–COVID-19 ARDS (96), whereas increased
NET formation is associated with ARDS and COVID19 severity, supporting a role for NETs in increased
thrombi risk in COVID-19 patients (88, 97–99).
SARS-CoV2 infection also elicits endotheliopathy,
which likely has a role in thrombotic events (100). Several
markers of platelet and endothelial activation/injury,
including soluble P-selectin, soluble thrombomodulin,
Critical Care Explorations

and von Willebrand factor (vWf), were higher in critically ill COVID-19 patients than in noncritically ill
patients and healthy controls, suggesting that platelets
and endothelial cells are involved in the infection pathophysiology. The frequency of thrombotic events is approximately nine-fold higher in COVID-19 patients
with dyslipidemia than in those without (101, 102).
A recent report linked dyslipidemia, hypertension,
and endotheliopathy and demonstrated that lipids (enhanced by low-density lipoproteins), rapid
blood flow, and a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13
(ADAMTS13) modulate the formation of secreted vWf
into long fibrils tethered to endothelial cells (103, 104).
These studies suggest causative links between platelets,
endothelial cells, and lipids in the venous and thrombotic events observed in COVID-19 patients and may
explain the need for therapeutic anticoagulation.
Another relevant hematologic perturbation is an association between blood type and COVID-19 frequency
and severity. A study of 2,173 COVID-19 patients reported that more COVID-19 cases had type A blood
(38% vs 32% community control) than type O blood
(26% vs 35% community control) (105). Although
there may be a protective effect of anti-A antibodies,
the type A antigen itself is likely to be involved in stabilizing vWf levels in blood, as blood group type A-vWf
is more resistant to proteolysis than blood group type
O-vWF (106, 107). African Americans with type A
blood have higher baseline vWf levels than Caucasians
(108), which could increase the risk of thrombotic
disorders. A/B blood types are similar across ethnic
groups and do not fully account for ethnic disparities
in COVID-19 disease. Ethnic groups most affected by
COVID-19 are more likely to inherit null traits for three
lesser-known blood antigens. 1) The Duffy antigen receptor for chemokines (DARC) is a glycoprotein receptor for Plasmodium falciparum and is expressed
on erythrocytes (109). 2) The DARC-null phenotype
confers resistance to malaria and is carried by 68% of
African Americans and 5% of Hispanics (110) compared with 0% of Caucasians and 0% Chinese (109).
DARC serves as a decoy receptor and is a “sink” for several chemokines; loss of the DARC receptor in COVID19 could enable the cytokine storm and ARDS (111). 3)
Lewis-null/Secretor-null individuals lack blood group
system (AB) glycosylated antigens along epithelial linings in airways, gut, and kidney (109). Lewis antigens
www.ccejournal.org
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Figure 3. Proposed mechanism for severe acute respiratory syndrome–associated coronavirus 2
(SARS-CoV-2)–induced coagulopathy and thrombotic microangiopathy. The SARS-CoV-2 virus
directly injures cells/tissues and induces local and systemic inflammatory cascades, which induce the
release of cytokines and damage/danger-associated molecular patterns (DAMPs) and activate three
interconnected procoagulation pathways. Coagulation factor XII is activated during the contact phase
of coagulation, thereby activating complement, thrombin, and a positive feedback loop for inflammation.
Inflammation damages endothelial cells, further activating thrombin and polymorphonucleated cells
(PMNs) via tumor necrosis factors (TNFs) and tissue factor (TF). Cytokines and DAMPs also directly
activate PMNs, which initiates the development of NETosis and activates platelets. Activated platelets,
neutrophil extracellular traps (NETs), and fibrin combine to form clinically significant clots in patients
with coronavirus disease 2019 infections. CLOT = clot formation, EC = endothelial cell, FXII = factor
XII, FXIIa = activated factor XII, HMWK = high molecular weight kininogen, NETosis = neutrophil
extracellular traps, PK = prekallikrein, Plt = platelet.

are fucosyl groups that are up-regulated in bronchial
epithelium after inflammation (112) and have discrete
roles in dendritic cell activation (113) and neutrophil
transepithelial migration (110). Secretor status promotes some viral infections and inhibits others (109),
although the effect on SARS-CoV-2 infection remains
unclear. Lewis-null/Secretor-null is a rare phenotype
that is three- to four-fold more frequent in African
Americans and Brazilians than in Whites and Chinese
(109). Thus, in addition to socioeconomic factors (e.g.,
healthcare access, nutrition, crowded housing, employment conditions) (114), DARC and Lewis-null/
Secretor-null alleles may contribute biological factors
that drive ethnic disparities in severe COVID-19.
8     www.ccejournal.org

Future research on
complement,
coagulation, platelet activation,
NETs, thrombotic microangiopathy (TMA), vWf,
ADAMTS13, RAS axis,
bradykinin, and blood
type in COVID-19 disease
will enhance our understanding of how SARSCoV-2 viral infection
affects numerous tissues
and organs through its
effect on the vasculature.
In addition, given recent
reports about the potential
protective effects of aspirin
therapy, the effects of antiplatelet agents (including
aspirin, colchicine or
P2Y12 inhibitors) in preventing thrombotic events
observed in COVID-19
patients should be further
investigated (115).
Cardiac Manifestations

Early population studies
on COVID-19 detected a
disproportionate number
of deaths in patients with
preexisting cardiovascular
disease (36, 116). Patients
with hypertension likely
have RAS axis dysregulation, which may increase morbidity and mortality. There is evidence that elevated
troponin and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels are mortality risk factors in
patients with and without preexisting cardiovascular
disease (117). COVID-19 patients without preexisting cardiovascular disease can develop cardiovascular manifestations such as arrhythmias, myocarditis,
and heart failure (117), and sudden cardiac failure
can occur 1–3 weeks after initial infection, even while
patients’ MOF is improving (116). These combined
results indicate that SARS-CoV-2 infection impacts
the cardiovascular system during both acute and convalescent phases.
March 2021 • Volume 3 • Number 3

Review Article

A simple hypothesis of SARS-CoV-2–induced cardiac dysfunction is through direct infection of the myocardium and/or coronary endothelium. ACE2 and
TMPRSS2 are expressed in both tissues; although the
myocardium could theoretically act as a host for SARSCoV-2, there are no documented reports myocardial
infection (118, 119). Viral RNA has been detected in
the bloodstream, but infectious viral particles have not
been isolated from blood, which may limit the potential for viral infection of myocardium or cardiac endothelium (69, 120–124). There are reports of viral
detection in myocardial tissue samples with possible
myocarditis, although this could be explained by migration of infected macrophages from the lung into the
myocardium (125–127).
An alternative hypothesis of SARS-CoV-2–induced
cardiac dysfunction is that the proposed hypercoagulable state predisposes patients to develop coronary artery thromboses and subsequent sudden heart
failure, with elevated troponin and NT-proBNP levels
reflecting direct myocardial injury. Only two studies
reported ST-segment elevation in COVID-19 patients
(128, 129), thus limiting current data in support of this
hypothesis. However, myocardial infarctions are unlikely to be a common occurrence in spite of the high
prevalence of hypercoagulability, as myocardial biomarkers are not detected at high frequency.
The prominent hyperinflammatory response may be
responsible for the cardiac manifestations of COVID-19
disease. Proinflammatory cytokines decrease left ventricular function and lead to left ventricle dilation
(130). Immune complexes and autoantibodies generated during hyperinflammatory states may precipitate acute cardiomyopathy (131). Hyperinflammatory
states associated with recruitment of macrophage and
T cells to the heart may cause substantial cardiac injury and the development of fulminant myocarditis
(121, 125, 131, 132). Research investigating the underlying mechanisms of hyperinflammation in COVID-19
should focus on its impact on cardiac function and the
development of myocarditis.
Gastrointestinal and Hepatic Involvement
Various symptoms and laboratory abnormalities indicative of gastrointestinal and hepatobiliary involvement have been reported in COVID-19 patients.
Reports of nausea, vomiting, diarrhea (up to 10%), and
Critical Care Explorations

abdominal discomfort are common, and SARS-CoV-2
RNA is detectable in the stool (133–135). Up to 31% of
patients with COVID-19-associated ARDS were found
to have elevated lipase levels without pancreatitis, suggesting possible impairment in pancreatic microcirculation (136). Liver injury is more common in those
with gastrointestinal symptoms and in the critically ill
(133, 137). Gastrointestinal symptoms correlate with
more severe COVID-19 illness (133). Possible routes
for COVID-19 involvement in gastrointestinal include
trachea-esophagus-ileum-colon and disruption of the
gut-liver and gut-pulmonary axes (133, 138). ACE2
and TMPRSS are expressed by absorptive enterocytes
in the small and large bowel and likely have mechanistic roles in gastrointestinal involvement (133, 138).
Once infected, enterocyte malabsorption may lead to
increased gastrointestinal wall permeability and enteric symptoms such as diarrhea (139).
In normal liver tissue, ACE2 expression in bile duct
epithelial cells (cholangiocytes) is higher than that in
hepatocytes (16, 133, 140). Hepatocyte ACE2 expression increases in chronic liver diseases and during
hypoxia (125, 133). Isolated severe liver injury is rare
and generally accompanies shock, respiratory failure,
cardiac insufficiency, and/or renal insufficiency (137).
Hepatocyte injury biomarkers (AST, ALT, LDH) may
be increased, whereas liver synthetic function may
be impaired as manifested by decreased albumin and
increased PT (137).
Pathologic examination of COVID-19 patients
may reveal moderate microvascular steatosis, mild
sinusoidal dilatation, minimal lymphocytic infiltration, mild lobular and portal activity, multifocal hepatic necrosis, and rarely canalicular cholestasis (126,
141–143). Intranuclear or intracytoplasmic viral inclusions have not been reported (126, 141). These results
suggest that COVID-19–mediated hepatic injury has
multifactorial etiology that may differ in individual
patients (144). Potential mechanisms include: 1) direct viral effects; 2) treatment-associated toxicity; 3)
underlying disease predisposing to secondary injury;
and 4) inflammatory response and other effects of severe illness (e.g., parenteral nutrition, hypotension,
hypoxia, mechanical ventilation with high positive
end-expiratory pressure [18–20 cm H2O]) (133, 144,
145). Identifying the subset of mechanisms that are operating for a given patient may enable personalization
of therapies to optimize outcomes.
www.ccejournal.org
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Renal Manifestations
The frequency of AKI in severe COVID-19 disease
appears variable. Cohort studies using consensus definitions report AKI rates of 0–39%, and 5–19% of critically
ill patients require renal replacement therapy (146–
151). The underlying pathophysiology of COVID-19–
associated AKI may share similarities with other forms
of multifactorial AKI in the setting of critical illness
(152, 153). Current evidence from postmortem samples
and limited biopsy series suggests a myriad of renal
injuries (154–156), predominantly loss of proximal tubular brush border and acute tubular injury or the presence of inflammatory cells/infiltrates, viral particles in
the parenchyma, and fibrin thrombi (in approximately
10% of samples). These results suggest a TMA/endothelial injury process (157) but do not identify a specific
cause of AKI. In many cases, injury may be from hypotension-induced ischemia and hemodynamic sequelae
of positive pressure ventilation that reduces renal perfusion, reduces cardiac output, and increases renal venous
pressures (158–162). Tubular injury may stem from
nephrotoxin exposure, which traditionally accounts for
up to 25% of all hospital-based AKI. Given the COVID19 polypharmacy in select scenarios, nephrotoxins undoubtedly complicate this issue (163).
There are conflicting reports regarding the virus
in urine, although SARS-CoV-2 RNA/particles have
been identified in urine (47, 154, 164, 165). In early
AKI with a slightly injured tubule, the virus Spike protein may bind the ACE2 receptor and enter renal tubular epithelial cells, where it can then replicate (55).
Epithelial cell entry may explain some of the pathologically observed renal injury patterns (16, 148). Genetic
variations in the ACE2 receptor may contribute to the
disproportionate impact of COVID-19 in certain subpopulations. Several reports suggested associations
between COVID-19–mediated AKI and collapsing
glomerulopathy (157, 166–168). Collapsing glomerulopathy is characterized by tuft collapse with podocyte
hypertrophy and intracytoplasmic protein resorption
droplets. It has been associated with high-risk APOL1
alleles in individuals of African descent, thus providing a biologic factor that may explain ethnic disparities in COVID-19 outcomes (168, 169). Collapsing
glomerulopathy has been associated with other viral
infections including HIV, Zika, and Dengue. The exact
mechanisms and links of collapsing glomerulopathy to
the APOL1 gene remain under intense investigation.
10     www.ccejournal.org

Future investigations into COVID-19–associated AKI
should examine the specific impact of ACE2 and apolipoprotein L1 on the development of severe AKI.
Neurologic Manifestations
CNS involvement of human coronavirus infections
has been extensively documented (170–172). CNS
manifestations of SARS-CoV-2 infection have been reported in 14–36% of hospitalized patients, including
altered mental status, temporary anosmia, seizures, encephalitis, and ischemic stroke (173–175). These CNS
pathologies may be related to direct viral neurotropism,
CNS migration of infected peripheral immune cells, or
secondary to systemic infection (176, 177). Autopsy of
COVID-19 patients revealed virus in brain tissue, primarily in neurons (64, 178). Neurons and the capillary
endothelium express ACE2 receptors, providing two
possible routes for brain invasion (59). Intranasal inoculation of SARS-CoV-2 in transgenic mice expressing human ACE2 resulted in rapid and widespread
infection of primarily neurons and astrocytes in the
brain (179). Anosmia is reported in patients infected
with SARS-CoV-1 and SARS-CoV-2, thus supporting this route of entry, but olfactory tract abnormalities have not been observed in MRI (174, 180, 181).
Coronaviruses infect macrophages and glial cells,
but there is currently little evidence that peripheral
immune cell infection leads to CNS access (182, 183).
COVID-19–induced MOF may result in brain tissue
hypoxia/ischemia and blood-brain barrier disruption,
thereby potentially allowing SARS-CoV-2 access to the
CNS via the blood stream, although further data are
needed to support this hypothesis. Further work also is
needed to optimize testing modalities and procedures
as the duration of SARS-CoV-2 in cerebrospinal fluid
after symptom onset is unknown.
Up to 31% of critically ill COVID-19 patients have
thromboembolic complications (184, 185). The frequency of ischemic stroke in COVID-19 patients is
currently unknown, although one retrospective study
reported an frequency as high as 2.8% in hospitalized
COVID-19 patients with severe disease (173). A case
series of six patients with COVID-19 and ischemic
stroke reported that patients had moderate to critical
disease and an 8–24-day interval from COVID-19
symptom onset to stroke symptoms (186). Possible
indications and patient selection criteria for systemic anticoagulation therapy to reduce stroke risk in
March 2021 • Volume 3 • Number 3
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COVID-19 patients remain to be determined, along
with any beneficial changes in the approach to systemic thrombolysis or endovascular therapy. Several
studies reported that mechanically ventilated COVID19 patients require unusually high levels of sedation
with a markedly higher frequency of delirium (187–
198). Increased delirium rates may be due to direct
virus or inflammation-mediated effects, greater sedation requirements, or other yet unidentified factors.
Influenza pandemics before the 20th century were
historically followed by increased reports of neuropsychiatric symptoms including psychosis, depression, anxiety, insomnia, and mania (199, 200). Recent
viral pandemics and epidemics (influenza H1N1,
SARS-CoV-1, and Middle East respiratory syndrome–
associated coronavirus) have been associated with neuropsychiatric sequelae including narcolepsy, seizures,
and demyelinating processes (201–203). It will be crucial to institute longitudinal studies to assess COVID-19
association with long-term neuropsychiatric sequelae
to determine the disease burden and identify possible therapeutic interventions, particularly given the
emerging recognition of post-ICU syndrome and
long-haul disease among COVID-19 survivors.
Endocrine Manifestations
Obesity and type 2 diabetes mellitus (DM) are important risk factors associated with COVID-19 severity,
morbidity, and mortality (204–207). Adiposity promotes chronic low-grade inflammation and immune
dysregulation, leading to a more robust inflammatory
response, profound adaptive immune suppression, and
reduced viral clearance during infection with SARSCoV-2. Patients with obesity or type 2 DM may have
a chronic endotheliopathy and prothrombotic state
associated with dyslipidemia and high levels of circulating vWf, as noted above (208); when combined
with COVID-19–mediated coagulation perturbations,
the risk of cardiovascular and CNS thrombotic events
increases (209).
Uncontrolled hyperglycemia is associated with poor
outcomes in COVID-19 (209, 210). This may result
from hyperglycemia-associated glycosylation of ACE2
and viral Spike proteins that facilitate entry into target
host cells, thus increasing viral loads and suppressing
viral clearance. Studies on SARS-CoV-1 suggest that
the virus may directly infiltrate ACE2-expressing pancreatic islet cells, thereby reducing insulin production
Critical Care Explorations

and causing hyperglycemia (210). It is currently unknown whether islet cell damage is transient or permanent in COVID-19 survivors. Growing evidence
suggests that SARS-CoV2 infection may trigger new
onset diabetes, either via direct pancreatic invasion or
due to the immune response to the virus (211–213).
Adrenal insufficiency is an uncommon early finding in COVID-19, and higher serum cortisol levels
have been associated with increased mortality (214).
Persistent fatigue and malaise following SARS-CoV-2
infection may be related to postinfection adrenal insufficiency. Direct viral CNS infiltration may enable
infection of pituitary gland cells, leading to transient
suppression of the hypothalamic-pituitary-adrenal
axis. Alternatively, adrenal insufficiency may be caused
by immune-mediated hypophysitis (215). Bilateral adrenal hemorrhage secondary to renal vein and adrenal
plexus thrombosis was reported in a COVID-19 patient who had positive antiphospholipid antibodies
(216). Systemic corticosteroid therapy has been quite
successful in treating patients with severe COVID-19,
which may reflect both the anti-inflammatory effects
of steroids but also partial treatment of adrenal
insufficiency.
Patients often develop low levels of thyroid-stimulating hormone and triiodothyronine during the early
phases of critical COVID-19 illness, which typically
normalize during recovery (215). Although this may
represent euthyroid sick syndrome, there is evidence
that SARS-CoV-1 virus can directly invade and affect
thyroid tissue (205, 217, 218). This could explain lateonset subacute thyroiditis observed in COVID-19
patients, possibly secondary to immune-mediated
processes that cause thyrotoxicosis to hypothyroidism.
However, these mechanisms have yet to be elucidated
(217, 218).
Dermatologic Manifestations
Cutaneous manifestations have been reported in
5–20% of symptomatic COVID-19 patients (219–221).
Erythematous macules or papules over the trunk and
extremities, comparable with those observed in other
viral exanthems, occur early in the infection and are the
most common cutaneous manifestation. The rash may
be pruritic, lasts for a median of 10 days, and generally is associated with a more favorable clinical course
(222). The exanthem results from perivascular dermatitis and vasculitis with neutrophilic and lymphocytic
www.ccejournal.org
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infiltration as a response to the virus (223). Urticaria,
with or without angioedema, comprises up to 20%
of the rashes observed in COVID-19, particularly in
those with more severe disease (224, 225). Vesicular
eruptions (similar to those of chickenpox) are associated with moderate disease severity, exhibit acantholysis with dyskeratosis, and may be due to a cytopathic
effect of viral invasion (226). Purpura or petechiae are
uncommon and have been reported in patients with
thrombocytopenia and coagulopathy (221). Livedo racemosa resembles livedo reticularis but is more diffuse
and likely secondary to small or medium vessel vasculopathy with occlusive microthrombi or immune complexes, complement deposition, and reperfusion injury.
The term “COVID toes” is used to describe a chilblainlike lesion in COVID-19 patients. Unlike their idiopathic counterpart, COVID-related chilblains occur in
the absence of exposure to cold. These acral lesions are
often the only presenting symptom of COVID-19 infection and are likely caused by immune complex deposition or microthrombi (227–231). Two recent studies
present comprehensive depictions of the most common
cutaneous manifestations of COVID-19 (230, 231).

among immunized individuals who become infected,
remains an unanswered question. For example, given
the now known early induction of cellular immune exhaustion by SARS-CoV-2 infection that limits T and B
cell responses, vaccine development must include induction of both of these responses including antiviral
CD8+ T cells to provide robust protection from severe
disease (232). However, it is unclear how patients that
have already acquired the disease when the optimal
time for vaccination should occur to maximize protection? In addition, the recent emergence of SARSCoV-2 variants raises additional translational research
questions: what is the nature of the immune response
triggered by such variants, and is their increased transmissibility a reflection of a distinct immune response?
Do these variants result in differential organ dysfunction among infected patients? The critical care research
community is well poised to merge basic science with
translational, clinical, and big data approaches to tackle
this devastating illness.

FUTURE AREAS FOR RESEARCH AND
CONCLUSIONS

We would like to thank the Society of Critical Care
Medicine and the Research Section for assistance in
developing this article.

The COVID-19 pandemic will persist well in to 2021
and beyond. Further investigations on the mechanisms underlying the frequency, prevention, and treatment of COVID-19–related organ failure are urgently
needed. The current hypotheses of hyper- and hypoinflammation driving the clinical disease course do not
facilitate consensus views for therapeutic approaches.
Future research should use multiomic methods to refine descriptive findings and identify relevant signaling pathways. These studies should include patients
with different age, sex, and race, as potential therapies
may not be efficacious across heterogeneous populations. Although a vaccine holds the most promise, it
is likely that adjunctive immunorestoration or antiviral therapies are needed to improve outcomes. These
approaches should be based on specific immune signaling pathways rather than observed changes in nonspecific biomarkers. Given that there are several distinct
strategies for vaccine development (messenger RNA,
viral vector, adjuvanted protein, and inactivated virus),
the impact of these different strategies on the immune
response, as well as the impact on organ dysfunction
12     www.ccejournal.org
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